On­coMed shares crushed as Cel­gene-part­nered lead drug flops and Bay­er takes a pass on op­tions

It’s a black day at On­coMed $OMED. A lit­tle more than a year af­ter its num­ber two drug foundered in a Phase II fail­ure, its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.